Table 3.
Challenges and solutions for limitations in current intervention studies in SIV/HIV microbiome research
Limitation category | Specific limitation | Proposed solution |
---|---|---|
Prebiotics and probiotics market proliferation | Marketed without research evidence, efficacy and safety variation | Stricter regulations, evidence-based marketing |
Heterogeneity in intervention studies | Dosage and duration heterogeneity, outcome inconsistency | Standardized intervention protocols, unified outcome measures |
FMT challenges | Donor profile uncertainty, antibiotic preconditioning consensus | Donor profile databases, clinical trials assessing preconditioning antibiotic regimens |
Effectiveness assessment and localization | Stool vs. tissue microbiota correlation, impact assessment challenges | Advanced diagnostic tools, in-depth impact studies |
Small sample sizes and short study duration | Limited sample size, short study duration | Larger, multicenter trials, extended study periods |
Study design | Lack of standardized protocols, study design variability | Protocol development committees for microbiota interventions |